# Oral Semaglutide Shows Superior Glycaemic Control.

*biotech · news · 2026-04-23 · Benzinga*

## Key points

- The PIONEER TEENS trial is the first to evaluate an oral GLP-1 receptor agonist in youth.
- Oral semaglutide reduced HbA1c by 0.83% versus placebo at 26 weeks in ages 10–17.
- Novo Nordisk plans to seek label expansion for Rybelsus and Ozempic pill in the U.S. and EU soon.
- Metformin fails to maintain glycaemic control in about half of adolescent patients with type 2 diabetes.

**Companies:** Novo Nordisk
**Countries:** United States, Europe

[Read the full story on Benzinga](https://www.benzinga.com/news/health-care/26/04/52006039/novo-nordisk-eyes-approval-for-potential-first-oral-glp-1-diabetes-pill-in-young-patients)

---

Canonical: https://newsio.io/n/924cd9a0-8064-46e2-ac22-3940cb8ee3a2/oral-semaglutide-shows-superior-glycaemic-control-novo-nordisk-expects-to-file-f
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works